✨ Your Portfolio is fetched and updated from zerodha.
Micro Miscellaneous

Checkpoint Trends Ltd.

CHECKPOINT

Market Cap
₹10 Cr.
P/E
399.84

Checkpoint Trends Ltd.

  • Rubra Medicaments
  • Vivanza Biosciences
  • Ganon Products
FAQs on Checkpoint Trends Ltd. Shareprice

Rubra Medicaments has given better returns compared to its competitors.
Rubra Medicaments has grown at ~49.21% over the last 4yrs while peers have grown at a median rate of 25.29%

Yes, Rubra Medicaments is expensive.
Latest PE of Rubra Medicaments is 399, while 3 year average PE is 44.72.
Also latest EV/EBITDA of Rubra Medicaments is 184 while 3yr average is 42.04.

View FAQ's On Business
Growth Table
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Balance Sheet
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Cash Flow
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Quarterly Results
  • Checkpoint Trends Ltd.
  • Vivanza Biosciences
  • Ganon Products
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Checkpoint Trends Ltd. Financials

Balance sheet of Rubra Medicaments is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Rubra Medicaments is increasing.
Latest net debt of Rubra Medicaments is -₹0.03 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹0.03 Crs.

The profit is oscillating.
The profit of Rubra Medicaments is ₹0.03 Crs for Mar 2024, -₹0.08 Crs for Mar 2023 and -₹0.04 Crs for Mar 2022

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Rubra Medicaments latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech